Loading clinical trials...
Loading clinical trials...
Study GIPF-001 is phase 3 study designed to determine the safety and efficacy of IFN-g 1b administered by subcutaneous injection; compared to placebo in patients with IPF who are unresponsive to stero...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
InterMune
NCT05842681 · Idiopathic Pulmonary Fibrosis
NCT06951217 · Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
NCT07194382 · Idiopathic Pulmonary Fibrosis (IPF)
NCT06238622 · Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
NCT07299695 · Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis
University of Washington Medical Center
Seattle, Washington
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions